ACRS - Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.

52W High

$5.17

52W Low

$1.05

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.29

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.28

EV/Revenue (<3 favorable)

6.09

P/S (TTM) (<3 favorable)

13.16

P/B (<3 favorable)

1.68

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

2.69%

Institutions (25–75% balanced)

86.19%

Shares Outstanding

108,332,000

Float

72,652,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

16,789,000

Gross Profit (TTM)

-36,301,000

EPS (TTM)

-1.57

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-9.51%

ROE (TTM) (>15% strong)

-1.01%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.36

Momentum

Bearish momentum

Value

0.1105

0.1255

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025